208 related articles for article (PubMed ID: 36131938)
1. Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4
Gigliotti CL; Boggio E; Favero F; Incarnato D; Santoro C; Oliviero S; Rojo JM; Zucchelli S; Persichetti F; Baldanzi G; Dianzani U; Corà D
Front Immunol; 2022; 13():915963. PubMed ID: 36131938
[TBL] [Abstract][Full Text] [Related]
2. ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naïve CD4+ T cells.
Mesturini R; Nicola S; Chiocchetti A; Bernardone IS; Castelli L; Bensi T; Ferretti M; Comi C; Dong C; Rojo JM; Yagi J; Dianzani U
Eur J Immunol; 2006 Oct; 36(10):2601-12. PubMed ID: 17013990
[TBL] [Abstract][Full Text] [Related]
3. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes.
Parry RV; Rumbley CA; Vandenberghe LH; June CH; Riley JL
J Immunol; 2003 Jul; 171(1):166-74. PubMed ID: 12816995
[TBL] [Abstract][Full Text] [Related]
4. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production.
Okamoto N; Tezuka K; Kato M; Abe R; Tsuji T
Biochem Biophys Res Commun; 2003 Oct; 310(3):691-702. PubMed ID: 14550257
[TBL] [Abstract][Full Text] [Related]
5. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.
McAdam AJ; Chang TT; Lumelsky AE; Greenfield EA; Boussiotis VA; Duke-Cohan JS; Chernova T; Malenkovich N; Jabs C; Kuchroo VK; Ling V; Collins M; Sharpe AH; Freeman GJ
J Immunol; 2000 Nov; 165(9):5035-40. PubMed ID: 11046032
[TBL] [Abstract][Full Text] [Related]
6. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Wiendl H; Neuhaus O; Mehling M; Wintterle S; Schreiner B; Mitsdoerffer M; Wienhold W; Weissert R; Wessels J; Hartung HP; Weller M; Tolosa E; Melms A
J Neuroimmunol; 2003 Jul; 140(1-2):177-87. PubMed ID: 12864987
[TBL] [Abstract][Full Text] [Related]
7. CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells.
Kaminski DA; Lee BO; Eaton SM; Haynes L; Randall TD
Immunology; 2009 Jul; 127(3):373-85. PubMed ID: 19191918
[TBL] [Abstract][Full Text] [Related]
8. ICOS-mediated costimulation on Th2 differentiation is achieved by the enhancement of IL-4 receptor-mediated signaling.
Watanabe M; Watanabe S; Hara Y; Harada Y; Kubo M; Tanabe K; Toma H; Abe R
J Immunol; 2005 Feb; 174(4):1989-96. PubMed ID: 15699127
[TBL] [Abstract][Full Text] [Related]
9. The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28.
Suh WK; Tafuri A; Berg-Brown NN; Shahinian A; Plyte S; Duncan GS; Okada H; Wakeham A; Odermatt B; Ohashi PS; Mak TW
J Immunol; 2004 May; 172(10):5917-23. PubMed ID: 15128772
[TBL] [Abstract][Full Text] [Related]
10. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors.
Riley JL; Mao M; Kobayashi S; Biery M; Burchard J; Cavet G; Gregson BP; June CH; Linsley PS
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11790-5. PubMed ID: 12195015
[TBL] [Abstract][Full Text] [Related]
11. Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).
Dillon SR; Evans LS; Lewis KE; Debrot S; Blair TC; Mudri S; Kleist K; Levin SD; Bhandari JG; Garrett L; Wolfson MF; Holland PM; Rixon MW; Peng SL
Arthritis Rheumatol; 2023 Aug; 75(8):1344-1356. PubMed ID: 36862144
[TBL] [Abstract][Full Text] [Related]
12. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS
Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952
[TBL] [Abstract][Full Text] [Related]
13. Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice.
Vidric M; Suh WK; Dianzani U; Mak TW; Watts TH
J Immunol; 2005 Dec; 175(11):7288-96. PubMed ID: 16301634
[TBL] [Abstract][Full Text] [Related]
14. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
15. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells.
Zhang J; Salojin KV; Gao JX; Cameron MJ; Bergerot I; Delovitch TL
J Immunol; 1999 Apr; 162(7):3819-29. PubMed ID: 10201899
[TBL] [Abstract][Full Text] [Related]
16. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
Orvain C; Cauvet A; Prudent A; Guignabert C; Thuillet R; Ottaviani M; Tu L; Duhalde F; Nicco C; Batteux F; Avouac J; Wang N; Seaberg MA; Dillon SR; Allanore Y
Arthritis Res Ther; 2022 Jan; 24(1):13. PubMed ID: 34986869
[TBL] [Abstract][Full Text] [Related]
17. AP-1 is involved in ICOS gene expression downstream of TCR/CD28 and cytokine receptor signaling.
Watanabe M; Nakajima S; Ohnuki K; Ogawa S; Yamashita M; Nakayama T; Murakami Y; Tanabe K; Abe R
Eur J Immunol; 2012 Jul; 42(7):1850-62. PubMed ID: 22585681
[TBL] [Abstract][Full Text] [Related]
18. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression.
Liu D; Suchard SJ; Nadler SG; Ford ML
PLoS One; 2015; 10(6):e0130490. PubMed ID: 26098894
[TBL] [Abstract][Full Text] [Related]
20. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
Wyatt MM; Huff LW; Nelson MH; Neal LR; Medvec AR; Rangel Rivera GO; Smith AS; Rivera Reyes AM; Knochelmann HM; Riley JL; Lesinski GB; Paulos CM
Mol Ther; 2023 Jul; 31(7):2120-2131. PubMed ID: 37081789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
